OncoCyte Corp - Asset Resilience Ratio
OncoCyte Corp (OCX) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check OCX strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2023)
This chart shows how OncoCyte Corp's Asset Resilience Ratio has changed over time. See debt-free asset ratio of OncoCyte Corp to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down OncoCyte Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is OncoCyte Corp worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: OncoCyte Corp maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
OncoCyte Corp Industry Peers by Asset Resilience Ratio
Compare OncoCyte Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Cryosite Ltd
AU:CTE |
Diagnostics & Research | 5.65% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for OncoCyte Corp (2013–2023)
The table below shows the annual Asset Resilience Ratio data for OncoCyte Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $74.89 Million | -- |
| 2022-12-31 | 0.43% | $433.00K | $100.09 Million | -0.13pp |
| 2021-12-31 | 0.57% | $904.00K | $159.56 Million | -0.65pp |
| 2020-12-31 | 1.22% | $675.00K | $55.42 Million | +0.27pp |
| 2019-12-31 | 0.95% | $379.00K | $39.86 Million | -3.55pp |
| 2018-12-31 | 4.50% | $428.00K | $9.52 Million | -2.94pp |
| 2017-12-31 | 7.44% | $760.00K | $10.22 Million | -8.04pp |
| 2016-12-31 | 15.48% | $2.24 Million | $14.45 Million | -4.47pp |
| 2015-12-31 | 19.96% | $2.54 Million | $12.73 Million | -31.65pp |
| 2014-12-31 | 51.60% | $3.28 Million | $6.36 Million | -4.27pp |
| 2013-12-31 | 55.87% | $4.63 Million | $8.29 Million | -- |
About OncoCyte Corp
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test tha… Read more